Cost-effectiveness of using recombinant factor VIIa (rFVIIa) in a massive transfusion protocol for severe blunt trauma

Abstract

INTRODUCTION: Although there is an apparent mortality benefit with massive transfusion protocols (MTP), blood products are associated with complications, such as acute respiratory distress syndrome (ARDS). Hemostatic adjuncts that limit transfusion requirements and return coagulation to baseline may be necessary. Although expensive, recombinant activated factor VII (rFVIIa) is associated with decreased blood transfusions and ARDS after trauma. Using a decision analysis framework, we evaluated the cost-effectiveness of using rFVIIa within a MTP for reducing transfusion requirements after blunt trauma, and subsequent transfusion related ARDS.